The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.

Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.

Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.

A slew of recent manufacturing issues at several Korean pharma firms have prompted calls for improved quality control at and a change in the country's co-bioequivalence study system for generics.